- Medical - Diagnostics & Research
- Healthcare
Laboratory Corporation of America Holdings
LH · US ·
NYSE
231.185
USD
+2.615
(1.13%)
-
5.34
EPS
-
43.25
P/E
-
19.5B
MARKET CAP
-
1.56%
DIV YIELD
Executives
Name | Title | Pay |
---|---|---|
Mr. Adam H. Schechter | President, Chief Executive Officer & Chairman | 4.66M |
Mr. Lance V. Berberian | Executive Vice President and Chief Information & Technology Officer | 877K |
Ms. Amy B. Summy | Executive Vice President & Chief Marketing Officer | -- |
Mr. Mark S. Schroeder | Executive Vice President, President of Diagnostics Laboratories & Chief Operating Officer | 1.43M |
Ms. Anita Z. Graham | Executive Vice President & Chief Human Resources Officer | 1.35M |
Ms. Sandra D. van der Vaart J.D. | Executive Vice President, Chief Legal Officer & Corporate Secretary | -- |
Christin O'Donnell | Vice President of Investor Relations | -- |
Dr. Brian J. Caveney J.D., M.D., M.P.H. | EVice President, President of Early Development Research Laboratories and Chief Medical & Scientific Officer | 1.3M |
Mr. Peter J. Wilkinson | Senior Vice President & Chief Accounting Officer | -- |
Mr. Glenn A. Eisenberg | Chief Financial Officer & Executive Vice President | 1.87M |
Insider Transactions
Date | Name | Title | Acquisition Or Disposition | Stock / Options | # of Shares | Price |
---|---|---|---|---|---|---|
2024-06-06 | Rothman Paul | director | D - M-Exempt | Restricted Stock Unit | 717 | 0 |
2024-06-06 | Rothman Paul | director | A - M-Exempt | Common Stock | 717 | 0 |
2024-05-14 | van der Vaart Sandra D | EVP, Chief Legal Officer | D - S-Sale | Common Stock | 1800 | 210.8268 |
2024-05-14 | van der Vaart Sandra D | EVP, Chief Legal Officer | D - S-Sale | Common Stock | 200 | 210.835 |
2024-04-30 | ANDERSON KERRII B | director | D - S-Sale | Common Stock | 250 | 204.135 |
2024-05-02 | ANDERSON KERRII B | director | D - S-Sale | Common Stock | 250 | 200.0981 |
2024-04-30 | EISENBERG GLENN A | Chief Financial Officer, EVP | A - M-Exempt | Common Stock | 10229 | 0 |
2024-04-30 | EISENBERG GLENN A | Chief Financial Officer, EVP | D - F-InKind | Common Stock | 4496 | 201.37 |
2024-04-30 | EISENBERG GLENN A | Chief Financial Officer, EVP | D - M-Exempt | Performance Share Unit | 10229 | 0 |
2024-04-29 | Wilkinson Peter J | SVP, Chief Accounting Officer | D - S-Sale | Common Stock | 2439 | 204.329 |
2024-04-15 | EISENBERG GLENN A | Chief Financial Officer, EVP | A - M-Exempt | Common Stock | 10229 | 0 |
2024-04-15 | EISENBERG GLENN A | Chief Financial Officer, EVP | D - F-InKind | Common Stock | 4496 | 203.32 |
2024-04-15 | EISENBERG GLENN A | Chief Financial Officer, EVP | D - M-Exempt | Restricted Stock Unit | 10229 | 0 |
2024-04-01 | Schroeder Mark S | EVP, Pres Diagnostics & COO | D - S-Sale | Common Stock | 6477 | 217.29 |
2024-04-01 | Summy Amy B. | EVP, Chief Marketing Officer | D - S-Sale | Common Stock | 3500 | 217.29 |
2024-04-01 | Bailey Megan D. | EVP, Chief Strategy Officer | D - M-Exempt | Restricted Stock Unit | 205 | 0 |
2024-04-01 | Bailey Megan D. | EVP, Chief Strategy Officer | A - M-Exempt | Common Stock | 205 | 0 |
2024-04-01 | Bailey Megan D. | EVP, Chief Strategy Officer | D - F-InKind | Common Stock | 69 | 216.35 |
2024-03-27 | van der Vaart Sandra D | EVP, Chief Legal Officer | A - M-Exempt | Common Stock | 6158 | 0 |
2024-03-27 | van der Vaart Sandra D | EVP, Chief Legal Officer | D - F-InKind | Common Stock | 2605 | 216.57 |
2024-03-28 | van der Vaart Sandra D | EVP, Chief Legal Officer | D - S-Sale | Common Stock | 3553 | 216.74 |
2024-03-27 | van der Vaart Sandra D | EVP, Chief Legal Officer | D - M-Exempt | Restricted Stock Unit | 6158 | 0 |
2024-03-27 | Caveney Brian J | EVP, Pres of ED, CMO & CSO | A - M-Exempt | Common Stock | 11556 | 0 |
2024-03-27 | Caveney Brian J | EVP, Pres of ED, CMO & CSO | D - F-InKind | Common Stock | 5061 | 216.57 |
2024-03-27 | Caveney Brian J | EVP, Pres of ED, CMO & CSO | D - M-Exempt | Restricted Stock Unit | 11556 | 0 |
2024-03-27 | Schroeder Mark S | EVP, Pres Diagnostics & COO | A - M-Exempt | Common Stock | 11556 | 0 |
2024-03-27 | Schroeder Mark S | EVP, Pres Diagnostics & COO | D - F-InKind | Common Stock | 5079 | 216.57 |
2024-03-27 | Schroeder Mark S | EVP, Pres Diagnostics & COO | D - M-Exempt | Restricted Stock Unit | 11556 | 0 |
2024-03-27 | Schechter Adam H | President and CEO | A - M-Exempt | Common Stock | 72435 | 0 |
2024-03-27 | Schechter Adam H | President and CEO | D - F-InKind | Common Stock | 31799 | 216.57 |
2024-03-27 | Schechter Adam H | President and CEO | D - M-Exempt | Restricted Stock Unit | 72435 | 0 |
2024-03-27 | DiVincenzo Jonathan P. | EVP, Pres, Central Labs & Intl | A - M-Exempt | Common Stock | 3012 | 0 |
2024-03-27 | DiVincenzo Jonathan P. | EVP, Pres, Central Labs & Intl | D - F-InKind | Common Stock | 952 | 216.57 |
2024-03-27 | DiVincenzo Jonathan P. | EVP, Pres, Central Labs & Intl | D - M-Exempt | Restricted Stock Unit | 3012 | 0 |
2024-03-27 | Wilkinson Peter J | SVP, Chief Accounting Officer | A - M-Exempt | Common Stock | 3079 | 0 |
2024-03-27 | Wilkinson Peter J | SVP, Chief Accounting Officer | D - F-InKind | Common Stock | 894 | 216.57 |
2024-03-27 | Wilkinson Peter J | SVP, Chief Accounting Officer | D - M-Exempt | Restricted Stock Unit | 3079 | 0 |
2024-03-27 | Summy Amy B. | EVP, Chief Marketing Officer | A - M-Exempt | Common Stock | 5778 | 0 |
2024-03-27 | Summy Amy B. | EVP, Chief Marketing Officer | D - F-InKind | Common Stock | 2162 | 216.57 |
2024-03-27 | Summy Amy B. | EVP, Chief Marketing Officer | D - M-Exempt | Restricted Stock Unit | 5778 | 0 |
2024-03-27 | EISENBERG GLENN A | Chief Financial Officer, EVP | A - M-Exempt | Common Stock | 20033 | 0 |
2024-03-27 | EISENBERG GLENN A | Chief Financial Officer, EVP | D - F-InKind | Common Stock | 8805 | 216.57 |
2024-03-27 | EISENBERG GLENN A | Chief Financial Officer, EVP | D - M-Exempt | Restricted Stock Unit | 20033 | 0 |
2024-03-27 | BERBERIAN LANCE | EVP, CIO & CTO | A - M-Exempt | Common Stock | 7697 | 0 |
2024-03-27 | BERBERIAN LANCE | EVP, CIO & CTO | D - F-InKind | Common Stock | 3299 | 216.57 |
2024-03-27 | BERBERIAN LANCE | EVP, CIO & CTO | D - M-Exempt | Restricted Stock Unit | 7697 | 0 |
2024-03-07 | Schroeder Mark S | EVP, Pres Diagnostics & COO | A - M-Exempt | Common Stock | 2119 | 117.09 |
2024-03-07 | Schroeder Mark S | EVP, Pres Diagnostics & COO | D - S-Sale | Common Stock | 5048 | 218.45 |
2024-03-07 | Schroeder Mark S | EVP, Pres Diagnostics & COO | D - M-Exempt | Non-qualified Stock Options | 2119 | 117.09 |
2024-03-07 | Summy Amy B. | EVP, Chief Marketing Officer | D - S-Sale | Common Stock | 227 | 218.45 |
2024-02-21 | EISENBERG GLENN A | Chief Financial Officer, EVP | A - M-Exempt | Common Stock | 14054 | 163.63 |
2024-02-21 | EISENBERG GLENN A | Chief Financial Officer, EVP | D - S-Sale | Common Stock | 18379 | 215.3661 |
2024-02-21 | EISENBERG GLENN A | Chief Financial Officer, EVP | D - S-Sale | Common Stock | 7907 | 215.6759 |
2024-02-21 | EISENBERG GLENN A | Chief Financial Officer, EVP | D - S-Sale | Common Stock | 6665 | 217.5205 |
2024-02-21 | EISENBERG GLENN A | Chief Financial Officer, EVP | D - S-Sale | Common Stock | 1553 | 217.9842 |
2024-02-21 | EISENBERG GLENN A | Chief Financial Officer, EVP | D - M-Exempt | Non-qualified Stock Options | 14054 | 163.63 |
2024-02-21 | DiVincenzo Jonathan P. | EVP, Pres, Central Labs & Intl | D - S-Sale | Common Stock | 500 | 215.4901 |
2024-02-13 | van der Vaart Sandra D | EVP, Chief Legal Officer | D - S-Sale | Common Stock | 237 | 226.45 |
2024-02-11 | Schechter Adam H | President & CEO | D - M-Exempt | Restricted Stock Unit | 2964 | 0 |
2024-02-11 | Schechter Adam H | President & CEO | A - M-Exempt | Common Stock | 2964 | 0 |
2024-02-12 | Schechter Adam H | President & CEO | D - F-InKind | Common Stock | 1231 | 227.45 |
2024-02-11 | EISENBERG GLENN A | Chief Financial Officer, EVP | A - M-Exempt | Common Stock | 807 | 0 |
2024-02-12 | EISENBERG GLENN A | Chief Financial Officer, EVP | D - F-InKind | Common Stock | 215 | 227.45 |
2024-02-11 | EISENBERG GLENN A | Chief Financial Officer, EVP | D - M-Exempt | Restricted Stock Unit | 807 | 0 |
2024-02-11 | DiVincenzo Jonathan P. | EVP, Pres, Central Labs & Intl | D - M-Exempt | Restricted Stock Unit | 201 | 0 |
2024-02-11 | DiVincenzo Jonathan P. | EVP, Pres, Central Labs & Intl | A - M-Exempt | Common Stock | 201 | 0 |
2024-02-12 | DiVincenzo Jonathan P. | EVP, Pres, Central Labs & Intl | D - F-InKind | Common Stock | 59 | 227.45 |
2024-02-11 | Caveney Brian J | EVP, Pres of ED, CMO & CSO | A - M-Exempt | Common Stock | 472 | 0 |
2024-02-12 | Caveney Brian J | EVP, Pres of ED, CMO & CSO | D - F-InKind | Common Stock | 137 | 227.45 |
2024-02-11 | Caveney Brian J | EVP, Pres of ED, CMO & CSO | D - M-Exempt | Restricted Stock Unit | 472 | 0 |
2024-02-11 | BERBERIAN LANCE | EVP, CIO & CTO | A - M-Exempt | Common Stock | 324 | 0 |
2024-02-12 | BERBERIAN LANCE | EVP, CIO & CTO | D - F-InKind | Common Stock | 87 | 227.45 |
2024-02-11 | BERBERIAN LANCE | EVP, CIO & CTO | D - M-Exempt | Restricted Stock Unit | 324 | 0 |
2024-02-11 | Schroeder Mark S | EVP, Pres Diagnostics & COO | D - M-Exempt | Restricted Stock Unit | 472 | 0 |
2024-02-11 | Schroeder Mark S | EVP, Pres Diagnostics & COO | A - M-Exempt | Common Stock | 472 | 0 |
2024-02-12 | Schroeder Mark S | EVP, Pres Diagnostics & COO | D - F-InKind | Common Stock | 126 | 227.45 |
2024-02-11 | Summy Amy B. | EVP, Chief Marketing Officer | D - M-Exempt | Restricted Stock Unit | 201 | 0 |
2024-02-11 | Summy Amy B. | EVP, Chief Marketing Officer | A - M-Exempt | Common Stock | 201 | 0 |
2024-02-12 | Summy Amy B. | EVP, Chief Marketing Officer | D - F-InKind | Common Stock | 66 | 227.45 |
2024-02-11 | van der Vaart Sandra D | EVP, Chief Legal Officer | D - M-Exempt | Restricted Stock Unit | 324 | 0 |
2024-02-11 | van der Vaart Sandra D | EVP, Chief Legal Officer | A - M-Exempt | Common Stock | 324 | 0 |
2024-02-12 | van der Vaart Sandra D | EVP, Chief Legal Officer | D - F-InKind | Common Stock | 87 | 227.45 |
2024-02-11 | Wilkinson Peter J | SVP, Chief Accounting Officer | D - M-Exempt | Restricted Stock Unit | 123 | 0 |
2024-02-11 | Wilkinson Peter J | SVP, Chief Accounting Officer | A - M-Exempt | Common Stock | 123 | 0 |
2024-02-12 | Wilkinson Peter J | SVP, Chief Accounting Officer | D - F-InKind | Common Stock | 43 | 227.45 |
2024-02-08 | van der Vaart Sandra D | EVP, Chief Legal Officer | D - S-Sale | Common Stock | 259 | 222.06 |
2024-02-06 | Schechter Adam H | President & CEO | A - A-Award | Restricted Stock Unit | 13380 | 0 |
2024-02-07 | Schechter Adam H | President & CEO | D - M-Exempt | Restricted Stock Unit | 3250 | 0 |
2024-02-07 | Schechter Adam H | President & CEO | A - M-Exempt | Common Stock | 3250 | 0 |
2024-02-07 | Schechter Adam H | President & CEO | D - F-InKind | Common Stock | 1149 | 223.71 |
2024-02-06 | Schechter Adam H | President & CEO | A - A-Award | Non-qualified Stock Options | 41400 | 222.28 |
2024-02-07 | EISENBERG GLENN A | Chief Financial Officer, EVP | A - M-Exempt | Common Stock | 885 | 0 |
2024-02-07 | EISENBERG GLENN A | Chief Financial Officer, EVP | D - F-InKind | Common Stock | 236 | 223.71 |
2024-02-06 | EISENBERG GLENN A | Chief Financial Officer, EVP | A - A-Award | Restricted Stock Unit | 2900 | 0 |
2024-02-07 | EISENBERG GLENN A | Chief Financial Officer, EVP | D - M-Exempt | Restricted Stock Unit | 885 | 0 |
2024-02-06 | EISENBERG GLENN A | Chief Financial Officer, EVP | A - A-Award | Non-qualified Stock Options | 9000 | 222.28 |
2024-02-06 | DiVincenzo Jonathan P. | EVP, Pres, Central Labs & Intl | A - A-Award | Restricted Stock Unit | 980 | 0 |
2024-02-07 | DiVincenzo Jonathan P. | EVP, Pres, Central Labs & Intl | D - M-Exempt | Restricted Stock Unit | 224 | 0 |
2024-02-07 | DiVincenzo Jonathan P. | EVP, Pres, Central Labs & Intl | D - M-Exempt | Restricted Stock Unit | 138 | 0 |
2024-02-07 | DiVincenzo Jonathan P. | EVP, Pres, Central Labs & Intl | A - M-Exempt | Common Stock | 138 | 0 |
2024-02-07 | DiVincenzo Jonathan P. | EVP, Pres, Central Labs & Intl | D - F-InKind | Common Stock | 41 | 223.71 |
2024-02-07 | DiVincenzo Jonathan P. | EVP, Pres, Central Labs & Intl | A - M-Exempt | Common Stock | 224 | 0 |
2024-02-07 | DiVincenzo Jonathan P. | EVP, Pres, Central Labs & Intl | D - F-InKind | Common Stock | 78 | 223.71 |
2024-02-06 | DiVincenzo Jonathan P. | EVP, Pres, Central Labs & Intl | A - A-Award | Non-qualified Stock Options | 3000 | 222.28 |
2024-02-07 | Caveney Brian J | EVP, Pres of ED, CMO & CSO | A - M-Exempt | Common Stock | 517 | 0 |
2024-02-07 | Caveney Brian J | EVP, Pres of ED, CMO & CSO | A - M-Exempt | Common Stock | 112 | 0 |
2024-02-07 | Caveney Brian J | EVP, Pres of ED, CMO & CSO | D - F-InKind | Common Stock | 33 | 223.71 |
2024-02-07 | Caveney Brian J | EVP, Pres of ED, CMO & CSO | D - F-InKind | Common Stock | 171 | 223.71 |
2024-02-06 | Caveney Brian J | EVP, Pres of ED, CMO & CSO | A - A-Award | Restricted Stock Unit | 2010 | 0 |
2024-02-07 | Caveney Brian J | EVP, Pres of ED, CMO & CSO | D - M-Exempt | Restricted Stock Unit | 517 | 0 |
2024-02-07 | Caveney Brian J | EVP, Pres of ED, CMO & CSO | D - M-Exempt | Restricted Stock Unit | 112 | 0 |
2024-02-06 | Caveney Brian J | EVP, Pres of ED, CMO & CSO | A - A-Award | Non-qualified Stock Options | 6200 | 222.28 |
2024-02-07 | BERBERIAN LANCE | EVP, CIO & CTO | A - M-Exempt | Common Stock | 353 | 0 |
2024-02-07 | BERBERIAN LANCE | EVP, CIO & CTO | D - F-InKind | Common Stock | 94 | 223.71 |
2024-02-06 | BERBERIAN LANCE | EVP, CIO & CTO | A - A-Award | Restricted Stock Unit | 1070 | 0 |
2024-02-07 | BERBERIAN LANCE | EVP, CIO & CTO | D - M-Exempt | Restricted Stock Unit | 353 | 0 |
2024-02-06 | BERBERIAN LANCE | EVP, CIO & CTO | A - A-Award | Non-qualified Stock Options | 3300 | 222.28 |
2024-02-06 | Bailey Megan D. | EVP, Chief Strategy Officer | A - A-Award | Restricted Stock Unit | 540 | 0 |
2024-02-07 | Bailey Megan D. | EVP, Chief Strategy Officer | D - M-Exempt | Restricted Stock Unit | 224 | 0 |
2024-02-07 | Bailey Megan D. | EVP, Chief Strategy Officer | D - M-Exempt | Restricted Stock Unit | 67 | 0 |
2024-02-06 | Bailey Megan D. | EVP, Chief Strategy Officer | A - A-Award | Non-qualified Stock Options | 1700 | 222.28 |
2024-02-07 | Bailey Megan D. | EVP, Chief Strategy Officer | A - M-Exempt | Common Stock | 224 | 0 |
2024-02-07 | Bailey Megan D. | EVP, Chief Strategy Officer | A - M-Exempt | Common Stock | 67 | 0 |
2024-02-07 | Bailey Megan D. | EVP, Chief Strategy Officer | D - F-InKind | Common Stock | 26 | 223.71 |
2024-02-07 | Bailey Megan D. | EVP, Chief Strategy Officer | D - F-InKind | Common Stock | 87 | 223.71 |
2024-02-06 | GRAHAM ANITA Z | EVP, CHRO | A - A-Award | Non-qualified Stock Options | 3000 | 222.28 |
2024-02-06 | GRAHAM ANITA Z | EVP, CHRO | A - A-Award | Restricted Stock Unit | 980 | 0 |
2024-02-07 | GRAHAM ANITA Z | EVP, CHRO | D - M-Exempt | Restricted Stock Unit | 369 | 0 |
2024-02-07 | GRAHAM ANITA Z | EVP, CHRO | A - M-Exempt | Common Stock | 369 | 0 |
2024-02-07 | GRAHAM ANITA Z | EVP, CHRO | D - F-InKind | Common Stock | 107 | 223.71 |
2024-02-06 | Schroeder Mark S | EVP, Pres Diagnostics & COO | A - A-Award | Restricted Stock Unit | 2230 | 0 |
2024-02-07 | Schroeder Mark S | EVP, Pres Diagnostics & COO | D - M-Exempt | Restricted Stock Unit | 517 | 0 |
2024-02-07 | Schroeder Mark S | EVP, Pres Diagnostics & COO | D - M-Exempt | Restricted Stock Unit | 163 | 0 |
2024-02-07 | Schroeder Mark S | EVP, Pres Diagnostics & COO | A - M-Exempt | Common Stock | 163 | 0 |
2024-02-07 | Schroeder Mark S | EVP, Pres Diagnostics & COO | A - M-Exempt | Common Stock | 517 | 0 |
2024-02-07 | Schroeder Mark S | EVP, Pres Diagnostics & COO | D - F-InKind | Common Stock | 44 | 223.71 |
2024-02-07 | Schroeder Mark S | EVP, Pres Diagnostics & COO | D - F-InKind | Common Stock | 138 | 223.71 |
2024-02-06 | Schroeder Mark S | EVP, Pres Diagnostics & COO | A - A-Award | Non-qualified Stock Options | 6900 | 222.28 |
2024-02-06 | Summy Amy B. | EVP, Chief Marketing Officer | A - A-Award | Restricted Stock Unit | 670 | 0 |
2024-02-07 | Summy Amy B. | EVP, Chief Marketing Officer | D - M-Exempt | Restricted Stock Unit | 224 | 0 |
2024-02-07 | Summy Amy B. | EVP, Chief Marketing Officer | A - M-Exempt | Common Stock | 224 | 0 |
2024-02-07 | Summy Amy B. | EVP, Chief Marketing Officer | D - F-InKind | Common Stock | 73 | 223.71 |
2024-02-06 | Summy Amy B. | EVP, Chief Marketing Officer | A - A-Award | Non-qualified Stock Options | 2100 | 222.28 |
2024-02-06 | van der Vaart Sandra D | EVP, Chief Legal Officer | A - A-Award | Restricted Stock Unit | 1160 | 0 |
2024-02-07 | van der Vaart Sandra D | EVP, Chief Legal Officer | D - M-Exempt | Restricted Stock Unit | 353 | 0 |
2024-02-07 | van der Vaart Sandra D | EVP, Chief Legal Officer | A - M-Exempt | Common Stock | 353 | 0 |
2024-02-07 | van der Vaart Sandra D | EVP, Chief Legal Officer | D - F-InKind | Common Stock | 94 | 223.71 |
2024-02-06 | van der Vaart Sandra D | EVP, Chief Legal Officer | A - A-Award | Non-qualified Stock Options | 3600 | 222.28 |
2024-02-06 | Wilkinson Peter J | SVP, Chief Accounting Officer | A - A-Award | Restricted Stock Unit | 400 | 0 |
2024-02-07 | Wilkinson Peter J | SVP, Chief Accounting Officer | D - M-Exempt | Restricted Stock Unit | 134 | 0 |
2024-02-07 | Wilkinson Peter J | SVP, Chief Accounting Officer | A - M-Exempt | Common Stock | 134 | 0 |
2024-02-07 | Wilkinson Peter J | SVP, Chief Accounting Officer | D - F-InKind | Common Stock | 46 | 223.71 |
2024-02-06 | Wilkinson Peter J | SVP, Chief Accounting Officer | A - A-Award | Non-qualified Stock Options | 1200 | 222.28 |
2024-02-06 | Rothman Paul | director | A - A-Award | Restricted Stock Unit | 944 | 0 |
2024-02-07 | Williams R Sanders | director | A - M-Exempt | Common Stock | 947 | 0 |
2024-02-06 | Williams R Sanders | director | A - A-Award | Restricted Stock Unit | 236 | 0 |
2024-02-07 | Williams R Sanders | director | D - M-Exempt | Restricted Stock Unit | 947 | 0 |
2024-02-07 | Wengel Kathryn E | director | A - M-Exempt | Common Stock | 947 | 0 |
2024-02-06 | Wengel Kathryn E | director | A - A-Award | Restricted Stock Unit | 944 | 0 |
2024-02-07 | Wengel Kathryn E | director | D - M-Exempt | Restricted Stock Unit | 947 | 0 |
2024-02-07 | Parham Richelle P | director | A - M-Exempt | Common Stock | 947 | 0 |
2024-02-06 | Parham Richelle P | director | A - A-Award | Restricted Stock Unit | 944 | 0 |
2024-02-07 | Parham Richelle P | director | D - M-Exempt | Restricted Stock Unit | 947 | 0 |
2024-02-07 | NEUPERT PETER M | director | A - M-Exempt | Common Stock | 947 | 0 |
2024-02-06 | NEUPERT PETER M | director | A - A-Award | Restricted Stock Unit | 944 | 0 |
2024-02-07 | NEUPERT PETER M | director | D - M-Exempt | Restricted Stock Unit | 947 | 0 |
2024-02-07 | Kong Garheng | director | A - M-Exempt | Common Stock | 947 | 0 |
2024-02-06 | Kong Garheng | director | A - A-Award | Restricted Stock Unit | 944 | 0 |
2024-02-07 | Kong Garheng | director | D - M-Exempt | Restricted Stock Unit | 947 | 0 |
2024-02-06 | Kliphouse Kirsten Marie | director | A - A-Award | Restricted Stock Unit | 944 | 0 |
2024-02-07 | Kliphouse Kirsten Marie | director | A - M-Exempt | Common Stock | 947 | 0 |
2024-02-07 | Kliphouse Kirsten Marie | director | D - M-Exempt | Restricted Stock Unit | 947 | 0 |
2024-02-07 | Gilliland Dwight Gary | director | A - M-Exempt | Common Stock | 947 | 0 |
2024-02-06 | Gilliland Dwight Gary | director | A - A-Award | Restricted Stock Unit | 944 | 0 |
2024-02-07 | Gilliland Dwight Gary | director | D - M-Exempt | Restricted Stock Unit | 947 | 0 |
2024-02-07 | Davis Jeffrey A. | director | A - M-Exempt | Common Stock | 947 | 0 |
2024-02-06 | Davis Jeffrey A. | director | A - A-Award | Restricted Stock Unit | 944 | 0 |
2024-02-07 | Davis Jeffrey A. | director | D - M-Exempt | Restricted Stock Unit | 947 | 0 |
2024-02-07 | BELINGARD JEAN-LUC | director | A - M-Exempt | Common Stock | 947 | 0 |
2024-02-07 | BELINGARD JEAN-LUC | director | D - F-InKind | Common Stock | 95 | 223.71 |
2024-02-06 | BELINGARD JEAN-LUC | director | A - A-Award | Restricted Stock Unit | 236 | 0 |
2024-02-07 | BELINGARD JEAN-LUC | director | D - M-Exempt | Restricted Stock Unit | 947 | 0 |
2024-02-07 | ANDERSON KERRII B | director | A - M-Exempt | Common Stock | 947 | 0 |
2024-02-06 | ANDERSON KERRII B | director | A - A-Award | Restricted Stock Unit | 944 | 0 |
2024-02-07 | ANDERSON KERRII B | director | D - M-Exempt | Restricted Stock Unit | 947 | 0 |
2024-02-02 | Wilkinson Peter J | SVP, Chief Accounting Officer | D - M-Exempt | Restricted Stock Unit | 131 | 0 |
2024-02-02 | Wilkinson Peter J | SVP, Chief Accounting Officer | A - M-Exempt | Common Stock | 131 | 0 |
2024-02-02 | Wilkinson Peter J | SVP, Chief Accounting Officer | D - F-InKind | Common Stock | 45 | 221.54 |
2024-02-02 | Summy Amy B. | EVP, Chief Marketing Officer | D - M-Exempt | Restricted Stock Unit | 246 | 0 |
2024-02-02 | Summy Amy B. | EVP, Chief Marketing Officer | A - M-Exempt | Common Stock | 246 | 0 |
2024-02-02 | Summy Amy B. | EVP, Chief Marketing Officer | D - F-InKind | Common Stock | 80 | 221.54 |
2024-02-02 | BERBERIAN LANCE | EVP, CIO & CTO | A - M-Exempt | Common Stock | 331 | 0 |
2024-02-02 | BERBERIAN LANCE | EVP, CIO & CTO | D - F-InKind | Common Stock | 89 | 221.54 |
2024-02-02 | BERBERIAN LANCE | EVP, CIO & CTO | D - M-Exempt | Restricted Stock Unit | 331 | 0 |
2024-02-02 | Caveney Brian J | EVP, Pres of ED, CMO & CSO | A - M-Exempt | Common Stock | 495 | 0 |
2024-02-02 | Caveney Brian J | EVP, Pres of ED, CMO & CSO | D - F-InKind | Common Stock | 166 | 221.54 |
2024-02-02 | Caveney Brian J | EVP, Pres of ED, CMO & CSO | D - M-Exempt | Restricted Stock Unit | 495 | 0 |
2024-02-02 | Schechter Adam H | President & CEO | D - M-Exempt | Restricted Stock Unit | 3094 | 0 |
2024-02-02 | Schechter Adam H | President & CEO | A - M-Exempt | Common Stock | 3094 | 0 |
2024-02-02 | Schechter Adam H | President & CEO | D - F-InKind | Common Stock | 822 | 221.54 |
2024-02-02 | DiVincenzo Jonathan P. | EVP, Pres, Central Labs & Intl | D - M-Exempt | Restricted Stock Unit | 246 | 0 |
2024-02-02 | DiVincenzo Jonathan P. | EVP, Pres, Central Labs & Intl | A - M-Exempt | Common Stock | 246 | 0 |
2024-02-02 | DiVincenzo Jonathan P. | EVP, Pres, Central Labs & Intl | D - F-InKind | Common Stock | 85 | 221.54 |
2024-02-02 | EISENBERG GLENN A | Chief Financial Officer, EVP | A - M-Exempt | Common Stock | 856 | 0 |
2024-02-02 | EISENBERG GLENN A | Chief Financial Officer, EVP | D - F-InKind | Common Stock | 228 | 221.54 |
2024-02-02 | EISENBERG GLENN A | Chief Financial Officer, EVP | D - M-Exempt | Restricted Stock Unit | 856 | 0 |
2024-02-02 | Schroeder Mark S | EVP, Pres Diagnostics & COO | D - M-Exempt | Restricted Stock Unit | 495 | 0 |
2024-02-02 | Schroeder Mark S | EVP, Pres Diagnostics & COO | A - M-Exempt | Common Stock | 495 | 0 |
2024-02-02 | Schroeder Mark S | EVP, Pres Diagnostics & COO | D - F-InKind | Common Stock | 132 | 221.54 |
2024-02-02 | van der Vaart Sandra D | EVP, Chief Legal Officer | A - M-Exempt | Common Stock | 264 | 0 |
2024-02-02 | van der Vaart Sandra D | EVP, Chief Legal Officer | D - M-Exempt | Restricted Stock Unit | 264 | 0 |
2024-02-02 | van der Vaart Sandra D | EVP, Chief Legal Officer | D - F-InKind | Common Stock | 71 | 221.54 |
2024-02-05 | van der Vaart Sandra D | EVP, Chief Legal Officer | D - S-Sale | Common Stock | 193 | 220.57 |
2023-12-15 | DiVincenzo Jonathan P. | EVP, Pres, Central Labs & Intl | D - M-Exempt | Restricted Stock Unit | 64 | 0 |
2023-12-15 | DiVincenzo Jonathan P. | EVP, Pres, Central Labs & Intl | A - M-Exempt | Common Stock | 64 | 0 |
2023-12-15 | DiVincenzo Jonathan P. | EVP, Pres, Central Labs & Intl | D - F-InKind | Common Stock | 19 | 219.5 |
2023-11-16 | Wilkinson Peter J | SVP, Chief Accounting Officer | D - S-Sale | Common Stock | 1384 | 210.713 |
2023-10-12 | Kliphouse Kirsten Marie | director | D - M-Exempt | Restricted Stock Unit | 372 | 0 |
2023-10-12 | Kliphouse Kirsten Marie | director | A - M-Exempt | Common Stock | 372 | 0 |
2023-08-08 | ANDERSON KERRII B | director | D - S-Sale | Common Stock | 5000 | 211.5665 |
2023-08-01 | Wilkinson Peter J | SVP, Chief Accounting Officer | D - M-Exempt | Restricted Stock Unit | 56 | 0 |
2023-08-01 | Wilkinson Peter J | SVP, Chief Accounting Officer | A - M-Exempt | Common Stock | 56 | 0 |
2023-08-01 | Wilkinson Peter J | SVP, Chief Accounting Officer | D - F-InKind | Common Stock | 17 | 213.61 |
2023-06-30 | van der Vaart Sandra D | EVP, Chief Legal Officer | A - A-Award | Restricted Stock Unit | 6207 | 0 |
2023-06-30 | Wilkinson Peter J | SVP, Chief Accounting Officer | A - A-Award | Restricted Stock Unit | 3104 | 0 |
2023-06-30 | Summy Amy B. | EVP, Chief Marketing Officer | A - A-Award | Restricted Stock Unit | 5824 | 0 |
2023-06-30 | Schroeder Mark S | EVP, Pres Diagnostics & COO | A - A-Award | Restricted Stock Unit | 11648 | 0 |
2023-06-30 | Schechter Adam H | President & CEO | A - A-Award | Restricted Stock Unit | 73013 | 0 |
2023-06-30 | EISENBERG GLENN A | Chief Financial Officer, EVP | A - A-Award | Restricted Stock Unit | 20193 | 0 |
2023-06-30 | DiVincenzo Jonathan P. | EVP, Pres, Central Labs & Intl | A - A-Award | Restricted Stock Unit | 3036 | 0 |
2023-06-30 | Caveney Brian J | EVP, Pres of ED, CMO & CSO | A - A-Award | Restricted Stock Unit | 11648 | 0 |
2023-06-30 | BERBERIAN LANCE | EVP, CIO & CTO | A - A-Award | Restricted Stock Unit | 7758 | 0 |
2023-06-29 | van der Vaart Sandra D | EVP, Chief Legal Officer | D - S-Sale | Common Stock | 212 | 240 |
2023-06-06 | Rothman Paul | director | A - A-Award | Restricted Stock Unit | 642 | 0 |
2023-06-06 | Rothman Paul | director | D - | Common Stock | 0 | 0 |
2023-05-19 | Kirchgraber Paul R | CEO, Covance Drug Development | A - M-Exempt | Common Stock | 4300 | 182.51 |
2023-05-19 | Kirchgraber Paul R | CEO, Covance Drug Development | D - S-Sale | Common Stock | 4300 | 216.9086 |
2023-05-19 | Kirchgraber Paul R | CEO, Covance Drug Development | D - M-Exempt | Non-qualified Stock Options | 4300 | 182.51 |
2023-05-18 | Schroeder Mark S | EVP, Pres Diagnostics & COO | A - M-Exempt | Common Stock | 1500 | 130.6 |
2023-05-18 | Schroeder Mark S | EVP, Pres Diagnostics & COO | D - S-Sale | Common Stock | 1500 | 216.77 |
2023-05-18 | Schroeder Mark S | EVP, Pres Diagnostics & COO | D - M-Exempt | Non-qualified Stock Options | 1500 | 130.6 |
2023-05-05 | Schroeder Mark S | EVP, Pres Diagnostics & COO | A - A-Award | Restricted Stock Unit | 440 | 0 |
2023-05-05 | Schroeder Mark S | EVP, Pres Diagnostics & COO | A - A-Award | Non-qualified Stock Options | 1400 | 223.86 |
2023-05-05 | Caveney Brian J | EVP, Pres of ED, CMO & CSO | A - A-Award | Restricted Stock Unit | 300 | 0 |
2023-05-05 | Caveney Brian J | EVP, Pres of ED, CMO & CSO | A - A-Award | Non-qualified Stock Options | 1000 | 223.86 |
2023-05-05 | Bailey Megan D. | EVP, Chief Strategy Officer | A - A-Award | Restricted Stock Unit | 180 | 0 |
2023-05-05 | Bailey Megan D. | EVP, Chief Strategy Officer | A - A-Award | Non-qualified Stock Options | 600 | 223.86 |
2023-05-05 | DiVincenzo Jonathan P. | EVP, Pres, Central Labs & Intl | A - A-Award | Restricted Stock Unit | 370 | 0 |
2023-05-05 | DiVincenzo Jonathan P. | EVP, Pres, Central Labs & Intl | A - A-Award | Non-qualified Stock Options | 1200 | 223.86 |
2023-05-01 | Bailey Megan D. | EVP, Chief Strategy Officer | D - | Common Stock | 0 | 0 |
2023-05-01 | Bailey Megan D. | EVP, Chief Strategy Officer | D - | Restricted Stock Unit | 3660 | 0 |
2023-05-01 | DiVincenzo Jonathan P. | EVP, Pres, Central Labs & Intl | D - | Common Stock | 0 | 0 |
2023-05-01 | DiVincenzo Jonathan P. | EVP, Pres, Central Labs & Intl | D - | Restricted Stock Unit | 360 | 0 |
2023-04-05 | GRAHAM ANITA Z | EVP, CHRO | A - A-Award | Non-qualified Stock Options | 3000 | 234.01 |
2023-04-05 | GRAHAM ANITA Z | EVP, CHRO | A - A-Award | Restricted Stock Unit | 990 | 0 |
2023-04-03 | GRAHAM ANITA Z | EVP, CHRO | D - | Common Stock | 0 | 0 |
2023-03-30 | Schechter Adam H | President & CEO | A - A-Award | Common Stock | 42353 | 0 |
2023-03-30 | Schechter Adam H | President & CEO | D - F-InKind | Common Stock | 18646 | 224.7 |
2023-03-30 | Kirchgraber Paul R | CEO, Covance Drug Development | A - A-Award | Common Stock | 6763 | 0 |
2023-03-30 | Kirchgraber Paul R | CEO, Covance Drug Development | D - F-InKind | Common Stock | 2886 | 224.7 |
2023-03-30 | EISENBERG GLENN A | Chief Financial Officer, EVP | A - A-Award | Common Stock | 11715 | 0 |
2023-03-30 | EISENBERG GLENN A | Chief Financial Officer, EVP | D - F-InKind | Common Stock | 5179 | 224.7 |
2023-03-30 | Caveney Brian J | EVP, President of Diagnostics | A - A-Award | Common Stock | 6763 | 0 |
2023-03-30 | Caveney Brian J | EVP, President of Diagnostics | D - F-InKind | Common Stock | 2990 | 224.7 |
2023-03-30 | BERBERIAN LANCE | EVP, CIO & CTO | A - A-Award | Common Stock | 4509 | 0 |
2023-03-30 | BERBERIAN LANCE | EVP, CIO & CTO | D - F-InKind | Common Stock | 1799 | 224.7 |
2023-03-30 | Schroeder Mark S | EVP, President-Diagnostics Lab | A - A-Award | Common Stock | 6763 | 0 |
2023-03-30 | Schroeder Mark S | EVP, President-Diagnostics Lab | D - F-InKind | Common Stock | 2866 | 224.7 |
2023-03-31 | Schroeder Mark S | EVP, President-Diagnostics Lab | D - S-Sale | Common Stock | 3897 | 225.81 |
2023-03-30 | Seltz Judith C | EVP, CHRO | A - A-Award | Common Stock | 3381 | 0 |
2023-03-30 | Seltz Judith C | EVP, CHRO | D - F-InKind | Common Stock | 1164 | 224.7 |
2023-03-30 | Summy Amy B. | EVP, Chief Marketing Officer | A - A-Award | Common Stock | 3234 | 0 |
2023-03-30 | Summy Amy B. | EVP, Chief Marketing Officer | D - F-InKind | Common Stock | 1269 | 224.7 |
2023-03-30 | van der Vaart Sandra D | EVP, Chief Legal Officer | A - A-Award | Common Stock | 3609 | 0 |
2023-03-30 | van der Vaart Sandra D | EVP, Chief Legal Officer | D - F-InKind | Common Stock | 1371 | 224.7 |
2023-03-30 | Wilkinson Peter J | SVP, Chief Accounting Officer | A - A-Award | Common Stock | 1798 | 0 |
2023-03-30 | Wilkinson Peter J | SVP, Chief Accounting Officer | D - F-InKind | Common Stock | 526 | 224.7 |
2023-03-02 | Summy Amy B. | EVP, Chief Marketing Officer | A - M-Exempt | Common Stock | 1340 | 0 |
2023-03-02 | Summy Amy B. | EVP, Chief Marketing Officer | D - F-InKind | Common Stock | 374 | 239.46 |
2023-03-02 | Summy Amy B. | EVP, Chief Marketing Officer | D - M-Exempt | Restricted Stock Unit | 1340 | 0 |
2023-02-21 | Kirchgraber Paul R | CEO, Covance Drug Development | A - M-Exempt | Common Stock | 3000 | 182.51 |
2023-02-21 | Kirchgraber Paul R | CEO, Covance Drug Development | D - S-Sale | Common Stock | 8000 | 250.5844 |
2023-02-21 | Kirchgraber Paul R | CEO, Covance Drug Development | D - M-Exempt | Non-qualified Stock Options | 3000 | 182.51 |
2023-02-14 | Schroeder Mark S | EVP, President-Diagnostics Lab | D - S-Sale | Common Stock | 309 | 247.63 |
2023-02-11 | BELINGARD JEAN-LUC | director | A - M-Exempt | Common Stock | 742 | 0 |
2023-02-13 | BELINGARD JEAN-LUC | director | D - F-InKind | Common Stock | 75 | 248.13 |
2023-02-11 | BELINGARD JEAN-LUC | director | D - M-Exempt | Restricted Stock Unit | 742 | 0 |
2023-02-11 | ANDERSON KERRII B | director | A - M-Exempt | Common Stock | 742 | 0 |
2023-02-11 | ANDERSON KERRII B | director | D - M-Exempt | Restricted Stock Unit | 742 | 0 |
2023-02-11 | Davis Jeffrey A. | director | A - M-Exempt | Common Stock | 742 | 0 |
2023-02-11 | Davis Jeffrey A. | director | D - M-Exempt | Restricted Stock Unit | 742 | 0 |
2023-02-11 | Gilliland Dwight Gary | director | A - M-Exempt | Common Stock | 742 | 0 |
2023-02-11 | Gilliland Dwight Gary | director | D - M-Exempt | Restricted Stock Unit | 742 | 0 |
2023-02-11 | Kong Garheng | director | A - M-Exempt | Common Stock | 742 | 0 |
2023-02-11 | Kong Garheng | director | D - M-Exempt | Restricted Stock Unit | 742 | 0 |
2023-02-11 | NEUPERT PETER M | director | A - M-Exempt | Common Stock | 742 | 0 |
2023-02-11 | NEUPERT PETER M | director | D - M-Exempt | Restricted Stock Unit | 742 | 0 |
2023-02-11 | Parham Richelle P | director | A - M-Exempt | Common Stock | 742 | 0 |
2023-02-11 | Parham Richelle P | director | D - M-Exempt | Restricted Stock Unit | 742 | 0 |
2023-02-11 | Wengel Kathryn E | director | A - M-Exempt | Common Stock | 742 | 0 |
2023-02-11 | Wengel Kathryn E | director | D - M-Exempt | Restricted Stock Unit | 742 | 0 |
2023-02-11 | Williams R Sanders | director | A - M-Exempt | Common Stock | 742 | 0 |
2023-02-11 | Williams R Sanders | director | D - M-Exempt | Restricted Stock Unit | 742 | 0 |
2023-02-11 | BERBERIAN LANCE | EVP, CIO & CTO | A - M-Exempt | Common Stock | 290 | 0 |
2023-02-13 | BERBERIAN LANCE | EVP, CIO & CTO | D - F-InKind | Common Stock | 85 | 248.13 |
2023-02-11 | BERBERIAN LANCE | EVP, CIO & CTO | D - M-Exempt | Restricted Stock Unit | 290 | 0 |
2023-02-11 | Caveney Brian J | EVP, President of Diagnostics | A - M-Exempt | Common Stock | 423 | 0 |
2023-02-13 | Caveney Brian J | EVP, President of Diagnostics | D - F-InKind | Common Stock | 124 | 248.13 |
2023-02-11 | Caveney Brian J | EVP, President of Diagnostics | D - M-Exempt | Restricted Stock Unit | 423 | 0 |
2023-02-11 | Kirchgraber Paul R | CEO, Covance Drug Development | A - M-Exempt | Common Stock | 483 | 0 |
2023-02-13 | Kirchgraber Paul R | CEO, Covance Drug Development | D - F-InKind | Common Stock | 142 | 248.13 |
2023-02-11 | Kirchgraber Paul R | CEO, Covance Drug Development | D - M-Exempt | Restricted Stock Unit | 483 | 0 |
2023-02-11 | EISENBERG GLENN A | Chief Financial Officer, EVP | A - M-Exempt | Common Stock | 723 | 0 |
2023-02-13 | EISENBERG GLENN A | Chief Financial Officer, EVP | D - F-InKind | Common Stock | 195 | 248.13 |
2023-02-11 | EISENBERG GLENN A | Chief Financial Officer, EVP | D - M-Exempt | Restricted Stock Unit | 723 | 0 |
2023-02-11 | Schechter Adam H | President & CEO | A - M-Exempt | Common Stock | 2656 | 0 |
2023-02-13 | Schechter Adam H | President & CEO | D - F-InKind | Common Stock | 1170 | 248.13 |
2023-02-11 | Schechter Adam H | President & CEO | D - M-Exempt | Restricted Stock Unit | 2656 | 0 |
2023-02-11 | Schroeder Mark S | EVP, President-Diagnostics Lab | A - M-Exempt | Common Stock | 423 | 0 |
2023-02-13 | Schroeder Mark S | EVP, President-Diagnostics Lab | D - F-InKind | Common Stock | 114 | 248.13 |
2023-02-11 | Schroeder Mark S | EVP, President-Diagnostics Lab | D - M-Exempt | Restricted Stock Unit | 423 | 0 |
2023-02-11 | Seltz Judith C | EVP, CHRO | A - M-Exempt | Common Stock | 236 | 0 |
2023-02-13 | Seltz Judith C | EVP, CHRO | D - F-InKind | Common Stock | 69 | 248.13 |
2023-02-11 | Seltz Judith C | EVP, CHRO | D - M-Exempt | Restricted Stock Unit | 236 | 0 |
2023-02-11 | Summy Amy B. | EVP, Chief Marketing Officer | D - M-Exempt | Restricted Stock Unit | 180 | 0 |
2023-02-11 | Summy Amy B. | EVP, Chief Marketing Officer | A - M-Exempt | Common Stock | 180 | 0 |
2023-02-13 | Summy Amy B. | EVP, Chief Marketing Officer | D - F-InKind | Common Stock | 54 | 248.13 |
2023-02-11 | van der Vaart Sandra D | EVP, Chief Legal Officer | A - M-Exempt | Common Stock | 290 | 0 |
2023-02-13 | van der Vaart Sandra D | EVP, Chief Legal Officer | D - F-InKind | Common Stock | 78 | 248.13 |
2023-02-11 | van der Vaart Sandra D | EVP, Chief Legal Officer | D - M-Exempt | Restricted Stock Unit | 290 | 0 |
2023-02-11 | Wilkinson Peter J | SVP, Chief Accounting Officer | A - M-Exempt | Common Stock | 110 | 0 |
2023-02-13 | Wilkinson Peter J | SVP, Chief Accounting Officer | D - F-InKind | Common Stock | 38 | 248.13 |
2023-02-11 | Wilkinson Peter J | SVP, Chief Accounting Officer | D - M-Exempt | Restricted Stock Unit | 110 | 0 |
2023-02-07 | Wilkinson Peter J | SVP, Chief Accounting Officer | A - A-Award | Non-qualified Stock Options | 1100 | 247.24 |
2023-02-07 | Wilkinson Peter J | SVP, Chief Accounting Officer | A - A-Award | Restricted Stock Unit | 360 | 0 |
2023-02-07 | Kong Garheng | director | A - A-Award | Restricted Stock Unit | 849 | 0 |
2023-02-07 | NEUPERT PETER M | director | A - A-Award | Restricted Stock Unit | 849 | 0 |
2023-02-07 | Kliphouse Kirsten Marie | director | A - A-Award | Restricted Stock Unit | 849 | 0 |
2023-02-07 | Wengel Kathryn E | director | A - A-Award | Restricted Stock Unit | 849 | 0 |
2023-02-07 | Williams R Sanders | director | A - A-Award | Restricted Stock Unit | 849 | 0 |
2023-02-07 | Gilliland Dwight Gary | director | A - A-Award | Restricted Stock Unit | 849 | 0 |
2023-02-07 | Davis Jeffrey A. | director | A - A-Award | Restricted Stock Unit | 849 | 0 |
2023-02-07 | ANDERSON KERRII B | director | A - A-Award | Restricted Stock Unit | 849 | 0 |
2023-02-07 | BELINGARD JEAN-LUC | director | A - A-Award | Restricted Stock Unit | 849 | 0 |
2023-02-07 | Parham Richelle P | director | A - A-Award | Restricted Stock Unit | 849 | 0 |
2023-02-07 | Kirchgraber Paul R | CEO, Covance Drug Development | A - A-Award | Non-qualified Stock Options | 5000 | 247.24 |
2023-02-07 | Kirchgraber Paul R | CEO, Covance Drug Development | A - A-Award | Restricted Stock Unit | 1590 | 0 |
2023-02-07 | Schechter Adam H | President & CEO | A - A-Award | Non-qualified Stock Options | 27400 | 247.24 |
2023-02-07 | Schechter Adam H | President & CEO | A - A-Award | Restricted Stock Unit | 8740 | 0 |
2023-02-07 | BERBERIAN LANCE | EVP, CIO & CTO | A - A-Award | Non-qualified Stock Options | 3000 | 247.24 |
2023-02-07 | BERBERIAN LANCE | EVP, CIO & CTO | A - A-Award | Restricted Stock Unit | 950 | 0 |
2023-02-07 | Caveney Brian J | EVP, President of Diagnostics | A - A-Award | Non-qualified Stock Options | 4400 | 247.24 |
2023-02-07 | Caveney Brian J | EVP, President of Diagnostics | A - A-Award | Restricted Stock Unit | 1390 | 0 |
2023-02-07 | EISENBERG GLENN A | Chief Financial Officer, EVP | A - A-Award | Restricted Stock Unit | 2380 | 0 |
2023-02-07 | EISENBERG GLENN A | Chief Financial Officer, EVP | A - A-Award | Non-qualified Stock Options | 7500 | 247.24 |
2023-02-07 | van der Vaart Sandra D | EVP, Chief Legal Officer | D - S-Sale | Common Stock | 219 | 243.01 |
2023-02-07 | van der Vaart Sandra D | EVP, Chief Legal Officer | A - A-Award | Non-qualified Stock Options | 3000 | 247.24 |
2023-02-07 | van der Vaart Sandra D | EVP, Chief Legal Officer | A - A-Award | Restricted Stock Unit | 950 | 0 |
2023-02-07 | Seltz Judith C | EVP, CHRO | A - A-Award | Non-qualified Stock Options | 2400 | 247.24 |
2023-02-07 | Seltz Judith C | EVP, CHRO | A - A-Award | Restricted Stock Unit | 770 | 0 |
2023-02-07 | Schroeder Mark S | EVP, President-Diagnostics Lab | D - S-Sale | Common Stock | 409 | 243.01 |
2023-02-07 | Schroeder Mark S | EVP, President-Diagnostics Lab | A - A-Award | Non-qualified Stock Options | 4400 | 247.24 |
2023-02-07 | Schroeder Mark S | EVP, President-Diagnostics Lab | A - A-Award | Restricted Stock Unit | 1390 | 0 |
2023-02-07 | Summy Amy B. | EVP, Chief Marketing Officer | A - A-Award | Restricted Stock Unit | 600 | 0 |
2023-02-07 | Summy Amy B. | EVP, Chief Marketing Officer | A - A-Award | Non-qualified Stock Options | 1900 | 247.24 |
2023-02-04 | Schechter Adam H | President & CEO | A - M-Exempt | Common Stock | 3507 | 0 |
2023-02-06 | Schechter Adam H | President & CEO | D - F-InKind | Common Stock | 1368 | 244.5 |
2023-02-04 | Schechter Adam H | President & CEO | D - M-Exempt | Restricted Stock Unit | 3507 | 0 |
2023-02-04 | Caveney Brian J | EVP, President of Diagnostics | A - M-Exempt | Common Stock | 560 | 0 |
2023-02-06 | Caveney Brian J | EVP, President of Diagnostics | D - F-InKind | Common Stock | 164 | 244.5 |
2023-02-04 | Caveney Brian J | EVP, President of Diagnostics | D - M-Exempt | Restricted Stock Unit | 560 | 0 |
2023-02-04 | BERBERIAN LANCE | EVP, CIO & CTO | A - M-Exempt | Common Stock | 374 | 0 |
2023-02-06 | BERBERIAN LANCE | EVP, CIO & CTO | D - F-InKind | Common Stock | 108 | 244.5 |
2023-02-04 | BERBERIAN LANCE | EVP, CIO & CTO | D - M-Exempt | Restricted Stock Unit | 374 | 0 |
2023-02-04 | EISENBERG GLENN A | Chief Financial Officer, EVP | A - M-Exempt | Common Stock | 970 | 0 |
2023-02-06 | EISENBERG GLENN A | Chief Financial Officer, EVP | D - F-InKind | Common Stock | 261 | 244.5 |
2023-02-04 | EISENBERG GLENN A | Chief Financial Officer, EVP | D - M-Exempt | Restricted Stock Unit | 970 | 0 |
2023-02-04 | Kirchgraber Paul R | CEO, Covance Drug Development | A - M-Exempt | Common Stock | 560 | 0 |
2023-02-06 | Kirchgraber Paul R | CEO, Covance Drug Development | D - F-InKind | Common Stock | 164 | 244.5 |
2023-02-04 | Kirchgraber Paul R | CEO, Covance Drug Development | D - M-Exempt | Restricted Stock Unit | 560 | 0 |
2023-02-04 | Schroeder Mark S | EVP, President-Diagnostics Lab | A - M-Exempt | Common Stock | 560 | 0 |
2023-02-06 | Schroeder Mark S | EVP, President-Diagnostics Lab | D - F-InKind | Common Stock | 151 | 244.5 |
2023-02-04 | Schroeder Mark S | EVP, President-Diagnostics Lab | D - M-Exempt | Restricted Stock Unit | 560 | 0 |
2023-02-04 | Seltz Judith C | EVP, CHRO | A - M-Exempt | Common Stock | 280 | 0 |
2023-02-06 | Seltz Judith C | EVP, CHRO | D - F-InKind | Common Stock | 84 | 244.5 |
2023-02-04 | Seltz Judith C | EVP, CHRO | D - M-Exempt | Restricted Stock Unit | 280 | 0 |
2023-02-04 | Summy Amy B. | EVP, Chief Marketing Officer | D - M-Exempt | Restricted Stock Unit | 267 | 0 |
2023-02-04 | Summy Amy B. | EVP, Chief Marketing Officer | A - M-Exempt | Common Stock | 267 | 0 |
2023-02-06 | Summy Amy B. | EVP, Chief Marketing Officer | D - F-InKind | Common Stock | 83 | 244.5 |
2023-02-04 | van der Vaart Sandra D | EVP, Chief Legal Officer | A - M-Exempt | Common Stock | 300 | 0 |
2023-02-06 | van der Vaart Sandra D | EVP, Chief Legal Officer | D - F-InKind | Common Stock | 81 | 244.5 |
2023-02-04 | van der Vaart Sandra D | EVP, Chief Legal Officer | D - M-Exempt | Restricted Stock Unit | 300 | 0 |
2023-02-04 | Wilkinson Peter J | SVP, Chief Accounting Officer | A - M-Exempt | Common Stock | 150 | 0 |
2023-02-06 | Wilkinson Peter J | SVP, Chief Accounting Officer | D - F-InKind | Common Stock | 52 | 244.5 |
2023-02-04 | Wilkinson Peter J | SVP, Chief Accounting Officer | D - M-Exempt | Restricted Stock Unit | 150 | 0 |
2023-02-02 | Seltz Judith C | EVP, CHRO | A - M-Exempt | Common Stock | 220 | 0 |
2023-02-02 | Seltz Judith C | EVP, CHRO | D - F-InKind | Common Stock | 77 | 254.99 |
2023-02-02 | Seltz Judith C | EVP, CHRO | D - M-Exempt | Restricted Stock Unit | 220 | 0 |
2023-02-02 | van der Vaart Sandra D | EVP, Chief Legal Officer | A - M-Exempt | Common Stock | 237 | 0 |
2023-02-02 | van der Vaart Sandra D | EVP, Chief Legal Officer | D - F-InKind | Common Stock | 64 | 254.99 |
2023-02-03 | van der Vaart Sandra D | EVP, Chief Legal Officer | D - S-Sale | Common Stock | 173 | 253.9 |
2023-02-02 | van der Vaart Sandra D | EVP, Chief Legal Officer | D - M-Exempt | Restricted Stock Unit | 237 | 0 |
2023-02-02 | Wilkinson Peter J | SVP, Chief Accounting Officer | A - M-Exempt | Common Stock | 117 | 0 |
2023-02-02 | Wilkinson Peter J | SVP, Chief Accounting Officer | D - F-InKind | Common Stock | 41 | 254.99 |
2023-02-02 | Wilkinson Peter J | SVP, Chief Accounting Officer | D - M-Exempt | Restricted Stock Unit | 117 | 0 |
2023-02-02 | Summy Amy B. | EVP, Chief Marketing Officer | D - M-Exempt | Restricted Stock Unit | 220 | 0 |
2023-02-02 | Summy Amy B. | EVP, Chief Marketing Officer | A - M-Exempt | Common Stock | 220 | 0 |
2023-02-02 | Summy Amy B. | EVP, Chief Marketing Officer | D - F-InKind | Common Stock | 77 | 254.99 |
2023-02-02 | Schroeder Mark S | EVP, President-Diagnostics Lab | A - M-Exempt | Common Stock | 443 | 0 |
2023-02-02 | Schroeder Mark S | EVP, President-Diagnostics Lab | D - F-InKind | Common Stock | 119 | 254.99 |
2023-02-03 | Schroeder Mark S | EVP, President-Diagnostics Lab | D - S-Sale | Common Stock | 324 | 253.9 |
2023-02-02 | Schroeder Mark S | EVP, President-Diagnostics Lab | D - M-Exempt | Restricted Stock Unit | 443 | 0 |
2023-02-02 | Schechter Adam H | President & CEO | A - M-Exempt | Common Stock | 2773 | 0 |
2023-02-02 | Schechter Adam H | President & CEO | D - F-InKind | Common Stock | 805 | 254.99 |
2023-02-02 | Schechter Adam H | President & CEO | D - M-Exempt | Restricted Stock Unit | 2773 | 0 |
2023-02-02 | Kirchgraber Paul R | CEO, Covance Drug Development | A - M-Exempt | Common Stock | 443 | 0 |
2023-02-02 | Kirchgraber Paul R | CEO, Covance Drug Development | D - F-InKind | Common Stock | 141 | 254.99 |
2023-02-02 | Kirchgraber Paul R | CEO, Covance Drug Development | D - M-Exempt | Restricted Stock Unit | 443 | 0 |
2023-02-02 | EISENBERG GLENN A | Chief Financial Officer, EVP | A - M-Exempt | Common Stock | 767 | 0 |
2023-02-02 | EISENBERG GLENN A | Chief Financial Officer, EVP | D - F-InKind | Common Stock | 206 | 254.99 |
2023-02-02 | EISENBERG GLENN A | Chief Financial Officer, EVP | D - M-Exempt | Restricted Stock Unit | 767 | 0 |
2023-02-02 | Caveney Brian J | EVP, President of Diagnostics | A - M-Exempt | Common Stock | 443 | 0 |
2023-02-02 | Caveney Brian J | EVP, President of Diagnostics | D - F-InKind | Common Stock | 144 | 254.99 |
2023-02-02 | Caveney Brian J | EVP, President of Diagnostics | D - M-Exempt | Restricted Stock Unit | 443 | 0 |
2023-02-02 | BERBERIAN LANCE | EVP, CIO & CTO | A - M-Exempt | Common Stock | 297 | 0 |
2023-02-02 | BERBERIAN LANCE | EVP, CIO & CTO | D - F-InKind | Common Stock | 102 | 254.99 |
2023-02-02 | BERBERIAN LANCE | EVP, CIO & CTO | D - M-Exempt | Restricted Stock Unit | 297 | 0 |
2023-01-09 | Pike Thomas | Pres & CEO Clinical Business | A - A-Award | Restricted Stock Unit | 16960 | 0 |
2023-01-09 | Pike Thomas | None | None - | None | None | None |
2023-01-09 | Pike Thomas | officer | - | 0 | 0 | |
2022-11-08 | Schroeder Mark S | EVP, President-Diagnostics Lab | D - S-Sale | Common Stock | 1116 | 232.67 |
2022-11-05 | Schroeder Mark S | EVP, President-Diagnostics Lab | A - M-Exempt | Common Stock | 2010 | 0 |
2022-11-07 | Schroeder Mark S | EVP, President-Diagnostics Lab | D - F-InKind | Common Stock | 894 | 233.77 |
2022-11-05 | Schroeder Mark S | EVP, President-Diagnostics Lab | D - M-Exempt | Restricted Stock Unit | 2010 | 0 |
2022-11-05 | Caveney Brian J | EVP, President of Diagnostics | A - M-Exempt | Common Stock | 2010 | 0 |
2022-11-07 | Caveney Brian J | EVP, President of Diagnostics | D - F-InKind | Common Stock | 894 | 233.77 |
2022-11-05 | Caveney Brian J | EVP, President of Diagnostics | D - M-Exempt | Restricted Stock Unit | 2010 | 0 |
2022-11-01 | EISENBERG GLENN A | Chief Financial Officer, EVP | A - M-Exempt | Common Stock | 12032 | 0 |
2022-11-01 | EISENBERG GLENN A | Chief Financial Officer, EVP | D - F-InKind | Common Stock | 5348 | 222.56 |
2022-11-01 | EISENBERG GLENN A | Chief Financial Officer, EVP | A - A-Award | Restricted Stock Unit | 9170 | 0 |
2022-11-01 | EISENBERG GLENN A | Chief Financial Officer, EVP | D - M-Exempt | Restricted Stock Unit | 12032 | 0 |
2022-11-01 | EISENBERG GLENN A | Chief Financial Officer, EVP | A - A-Award | Performance Share Unit | 9170 | 0 |
2022-11-01 | Schechter Adam H | President & CEO | A - M-Exempt | Common Stock | 2007 | 0 |
2022-11-01 | Schechter Adam H | President & CEO | D - F-InKind | Common Stock | 893 | 222.56 |
2022-11-01 | Schechter Adam H | President & CEO | D - M-Exempt | Restricted Stock Unit | 2007 | 0 |
2022-11-01 | Kirchgraber Paul R | CEO, Covance Drug Development | A - M-Exempt | Common Stock | 2007 | 0 |
2022-11-01 | Kirchgraber Paul R | CEO, Covance Drug Development | D - F-InKind | Common Stock | 892 | 222.56 |
2022-11-01 | Kirchgraber Paul R | CEO, Covance Drug Development | D - M-Exempt | Restricted Stock Unit | 2007 | 0 |
2022-10-12 | Kliphouse Kirsten Marie | director | A - A-Award | Restricted Stock Unit | 333 | 0 |
2022-10-12 | Kliphouse Kirsten Marie | None | None - | None | None | None |
2022-10-12 | Kliphouse Kirsten Marie | - | 0 | 0 | ||
2022-09-26 | EISENBERG GLENN A | Chief Financial Officer, EVP | D - S-Sale | Common Stock | 5627 | 209.294 |
2022-09-26 | EISENBERG GLENN A | Chief Financial Officer, EVP | D - S-Sale | Common Stock | 4844 | 210.2068 |
2022-09-26 | EISENBERG GLENN A | Chief Financial Officer, EVP | D - S-Sale | Common Stock | 11699 | 211.1346 |
2022-09-26 | EISENBERG GLENN A | Chief Financial Officer, EVP | D - S-Sale | Common Stock | 2830 | 211.8634 |
2022-08-03 | EISENBERG GLENN A | Chief Financial Officer, EVP | A - M-Exempt | Common Stock | 11600 | 146.59 |
2022-08-03 | EISENBERG GLENN A | Chief Financial Officer, EVP | D - S-Sale | Common Stock | 11262 | 253.265 |
2022-08-03 | EISENBERG GLENN A | Chief Financial Officer, EVP | A - M-Exempt | Common Stock | 9100 | 168.49 |
2022-08-03 | EISENBERG GLENN A | Chief Financial Officer, EVP | A - M-Exempt | Common Stock | 11400 | 130.6 |
2022-08-03 | EISENBERG GLENN A | Chief Financial Officer, EVP | D - S-Sale | Common Stock | 19338 | 254.259 |
2022-08-03 | EISENBERG GLENN A | Chief Financial Officer, EVP | D - S-Sale | Common Stock | 1500 | 254.879 |
2022-08-03 | EISENBERG GLENN A | Chief Financial Officer, EVP | D - M-Exempt | Non-qualified Stock Options | 9100 | 168.49 |
2022-08-03 | EISENBERG GLENN A | Chief Financial Officer, EVP | D - M-Exempt | Non-qualified Stock Options | 11600 | 0 |
2022-08-03 | EISENBERG GLENN A | Chief Financial Officer, EVP | D - M-Exempt | Non-qualified Stock Options | 11400 | 130.6 |
2022-08-03 | EISENBERG GLENN A | Chief Financial Officer, EVP | D - M-Exempt | Non-qualified Stock Options | 11600 | 146.59 |
2022-08-01 | Wilkinson Peter J | SVP, Chief Accounting Officer | A - M-Exempt | Common Stock | 767 | 146.59 |
2022-08-01 | Wilkinson Peter J | SVP, Chief Accounting Officer | A - M-Exempt | Common Stock | 50 | 0 |
2022-08-01 | Wilkinson Peter J | SVP, Chief Accounting Officer | D - F-InKind | Common Stock | 23 | 257.94 |
2022-08-01 | Wilkinson Peter J | SVP, Chief Accounting Officer | D - S-Sale | Common Stock | 757 | 258.6 |
2022-08-01 | Wilkinson Peter J | SVP, Chief Accounting Officer | D - S-Sale | Common Stock | 1809 | 258.3125 |
2022-08-01 | Wilkinson Peter J | SVP, Chief Accounting Officer | D - S-Sale | Common Stock | 10 | 258.705 |
2022-08-01 | Wilkinson Peter J | SVP, Chief Accounting Officer | D - M-Exempt | Restricted Stock Unit | 50 | 0 |
2022-08-01 | Wilkinson Peter J | SVP, Chief Accounting Officer | D - M-Exempt | Non-qualified Stock Options | 767 | 146.59 |
2022-06-07 | Caveney Brian J | EVP, President of Diagnostics | A - P-Purchase | Common Stock | 42.006 | 242.193 |
2022-03-29 | Schroeder Mark S | EVP, President-Diagnostics Lab | D - S-Sale | Common Stock | 2356 | 277.11 |
2022-03-29 | van der Vaart Sandra D | EVP, Chief Legal Officer | D - S-Sale | Common Stock | 2449 | 277.11 |
2022-03-27 | BERBERIAN LANCE | EVP, CIO & CTO | A - A-Award | Common Stock | 5310 | 0 |
2022-03-27 | BERBERIAN LANCE | EVP, CIO & CTO | D - F-InKind | Common Stock | 2360 | 276.42 |
2022-03-27 | Caveney Brian J | EVP, President of Diagnostics | A - A-Award | Common Stock | 4241 | 0 |
2022-03-27 | Caveney Brian J | EVP, President of Diagnostics | D - F-InKind | Common Stock | 1883 | 276.42 |
2022-03-27 | EISENBERG GLENN A | Chief Financial Officer, EVP | A - A-Award | Common Stock | 14144 | 0 |
2022-03-27 | EISENBERG GLENN A | Chief Financial Officer, EVP | D - F-InKind | Common Stock | 6286 | 276.42 |
2022-03-27 | Kirchgraber Paul R | CEO, Covance Drug Development | A - A-Award | Common Stock | 3707 | 0 |
2022-03-27 | Kirchgraber Paul R | CEO, Covance Drug Development | D - F-InKind | Common Stock | 1648 | 276.42 |
2022-03-27 | Schroeder Mark S | EVP, President-Diagnostics Lab | A - A-Award | Common Stock | 4241 | 0 |
2022-03-27 | Schroeder Mark S | EVP, President-Diagnostics Lab | D - F-InKind | Common Stock | 1885 | 276.42 |
2022-03-27 | van der Vaart Sandra D | EVP, Chief Legal Officer | A - A-Award | Common Stock | 4241 | 0 |
2022-03-27 | van der Vaart Sandra D | EVP, Chief Legal Officer | D - F-InKind | Common Stock | 1792 | 276.42 |
2022-03-27 | Wilkinson Peter J | SVP, Chief Accounting Officer | A - A-Award | Common Stock | 2822 | 0 |
2022-03-27 | Wilkinson Peter J | SVP, Chief Accounting Officer | D - F-InKind | Common Stock | 915 | 276.42 |
2022-03-25 | Wengel Kathryn E | A - M-Exempt | Common Stock | 603 | 0 | |
2022-03-25 | Williams R Sanders | D - S-Sale | Common Stock | 572 | 272.98 | |
2022-03-10 | Summy Amy B. | EVP, Chief Marketing Officer | D - S-Sale | Common Stock | 249 | 262.21 |
2022-02-16 | NEUPERT PETER M | director | A - P-Purchase | Common Stock | 600 | 264.57 |
2022-02-16 | NEUPERT PETER M | director | A - P-Purchase | Common Stock | 1600 | 263.98 |
2022-02-16 | NEUPERT PETER M | director | A - P-Purchase | Common Stock | 1300 | 262.85 |
2022-02-15 | Schroeder Mark S | EVP, President-Diagnostics Lab | D - S-Sale | Common Stock | 207 | 273.98 |
2022-02-15 | van der Vaart Sandra D | EVP, Chief Legal Officer | D - S-Sale | Common Stock | 207 | 273.98 |
2022-02-11 | Williams R Sanders | director | A - A-Award | Restricted Stock Unit | 742 | 0 |
2022-02-12 | Wilkinson Peter J | SVP, Chief Accounting Officer | A - M-Exempt | Common Stock | 680 | 0 |
2022-02-14 | Wilkinson Peter J | SVP, Chief Accounting Officer | D - F-InKind | Common Stock | 61 | 272.68 |
2022-02-14 | Wilkinson Peter J | SVP, Chief Accounting Officer | D - F-InKind | Common Stock | 200 | 272.68 |
2022-02-11 | Wilkinson Peter J | SVP, Chief Accounting Officer | A - A-Award | Restricted Stock Unit | 330 | 0 |
2022-02-12 | Wilkinson Peter J | SVP, Chief Accounting Officer | D - M-Exempt | Restricted Stock Unit | 187 | 0 |
2022-02-12 | Wilkinson Peter J | SVP, Chief Accounting Officer | A - M-Exempt | Common Stock | 187 | 0 |
2022-02-11 | Wilkinson Peter J | SVP, Chief Accounting Officer | A - A-Award | Non-qualified Stock Options | 1100 | 276.26 |
2022-02-12 | Wilkinson Peter J | SVP, Chief Accounting Officer | D - M-Exempt | Restricted Stock Unit | 680 | 0 |
2022-02-12 | Caveney Brian J | EVP, President of Diagnostics | A - M-Exempt | Common Stock | 2354 | 0 |
2022-02-14 | Caveney Brian J | EVP, President of Diagnostics | D - F-InKind | Common Stock | 84 | 272.68 |
2022-02-14 | Caveney Brian J | EVP, President of Diagnostics | D - F-InKind | Common Stock | 694 | 272.68 |
2022-02-12 | Caveney Brian J | EVP, President of Diagnostics | A - M-Exempt | Common Stock | 284 | 0 |
2022-02-11 | Caveney Brian J | EVP, President of Diagnostics | A - A-Award | Restricted Stock Unit | 1270 | 0 |
2022-02-12 | Caveney Brian J | EVP, President of Diagnostics | D - M-Exempt | Restricted Stock Unit | 284 | 0 |
2022-02-12 | Caveney Brian J | EVP, President of Diagnostics | D - M-Exempt | Restricted Stock Unit | 2354 | 0 |
2022-02-11 | Caveney Brian J | EVP, President of Diagnostics | A - A-Award | Non-qualified Stock Options | 4500 | 276.26 |
2022-02-12 | EISENBERG GLENN A | Chief Financial Officer, EVP | A - M-Exempt | Common Stock | 940 | 0 |
2022-02-14 | EISENBERG GLENN A | Chief Financial Officer, EVP | D - F-InKind | Common Stock | 277 | 272.68 |
2022-02-11 | EISENBERG GLENN A | Chief Financial Officer, EVP | A - A-Award | Restricted Stock Unit | 2170 | 0 |
2022-02-12 | EISENBERG GLENN A | Chief Financial Officer, EVP | D - M-Exempt | Restricted Stock Unit | 940 | 0 |
2022-02-11 | EISENBERG GLENN A | Chief Financial Officer, EVP | A - A-Award | Non-qualified Stock Options | 7700 | 276.26 |
2022-02-12 | Kirchgraber Paul R | CEO, Covance Drug Development | A - M-Exempt | Common Stock | 317 | 0 |
2022-02-14 | Kirchgraber Paul R | CEO, Covance Drug Development | D - F-InKind | Common Stock | 108 | 272.68 |
2022-02-11 | Kirchgraber Paul R | CEO, Covance Drug Development | A - A-Award | Restricted Stock Unit | 1450 | 0 |
2022-02-11 | Kirchgraber Paul R | CEO, Covance Drug Development | A - A-Award | Non-qualified Stock Options | 5100 | 276.26 |
2022-02-12 | Kirchgraber Paul R | CEO, Covance Drug Development | D - M-Exempt | Restricted Stock Unit | 317 | 0 |
2022-02-12 | BERBERIAN LANCE | EVP, CIO & CTO | A - M-Exempt | Common Stock | 354 | 0 |
2022-02-12 | BERBERIAN LANCE | EVP, CIO & CTO | A - M-Exempt | Common Stock | 2354 | 0 |
2022-02-14 | BERBERIAN LANCE | EVP, CIO & CTO | D - F-InKind | Common Stock | 694 | 272.68 |
2022-02-14 | BERBERIAN LANCE | EVP, CIO & CTO | D - F-InKind | Common Stock | 105 | 272.68 |
2022-02-11 | BERBERIAN LANCE | EVP, CIO & CTO | A - A-Award | Restricted Stock Unit | 870 | 0 |
2022-02-11 | BERBERIAN LANCE | EVP, CIO & CTO | A - A-Award | Non-qualified Stock Options | 3100 | 276.26 |
2022-02-12 | BERBERIAN LANCE | EVP, CIO & CTO | D - M-Exempt | Restricted Stock Unit | 2354 | 0 |
2022-02-12 | BERBERIAN LANCE | EVP, CIO & CTO | D - M-Exempt | Restricted Stock Unit | 354 | 0 |
2022-02-12 | Schroeder Mark S | EVP, President-Diagnostics Lab | A - M-Exempt | Common Stock | 284 | 0 |
2022-02-14 | Schroeder Mark S | EVP, President-Diagnostics Lab | D - F-InKind | Common Stock | 77 | 272.68 |
2022-02-11 | Schroeder Mark S | EVP, President-Diagnostics Lab | A - A-Award | Restricted Stock Unit | 1270 | 0 |
2022-02-12 | Schroeder Mark S | EVP, President-Diagnostics Lab | D - M-Exempt | Restricted Stock Unit | 284 | 0 |
2022-02-11 | Schroeder Mark S | EVP, President-Diagnostics Lab | A - A-Award | Non-qualified Stock Options | 4500 | 276.26 |
2022-02-12 | van der Vaart Sandra D | EVP, Chief Legal Officer | A - M-Exempt | Common Stock | 284 | 0 |
2022-02-14 | van der Vaart Sandra D | EVP, Chief Legal Officer | D - F-InKind | Common Stock | 77 | 272.68 |
2022-02-11 | van der Vaart Sandra D | EVP, Chief Legal Officer | A - A-Award | Non-qualified Stock Options | 3100 | 276.26 |
2022-02-11 | van der Vaart Sandra D | EVP, Chief Legal Officer | A - A-Award | Restricted Stock Unit | 870 | 0 |
2022-02-12 | van der Vaart Sandra D | EVP, Chief Legal Officer | D - M-Exempt | Restricted Stock Unit | 284 | 0 |
2022-02-11 | Schechter Adam H | President & CEO | A - A-Award | Non-qualified Stock Options | 28100 | 276.26 |
2022-02-11 | Schechter Adam H | President & CEO | A - A-Award | Restricted Stock Unit | 7970 | 0 |
2022-02-11 | Seltz Judith C | EVP, CHRO | A - A-Award | Non-qualified Stock Options | 2500 | 276.26 |
2022-02-11 | Seltz Judith C | EVP, CHRO | A - A-Award | Restricted Stock Unit | 710 | 0 |
2022-02-11 | Summy Amy B. | EVP, Chief Marketing Officer | A - A-Award | Restricted Stock Unit | 540 | 0 |
2022-02-11 | Summy Amy B. | EVP, Chief Marketing Officer | A - A-Award | Non-qualified Stock Options | 1900 | 276.26 |
2022-02-11 | Williams R Sanders | director | A - A-Award | Restricted Stock Unit | 742 | 0 |
2022-02-11 | Wengel Kathryn E | director | A - A-Award | Restricted Stock Unit | 742 | 0 |
2022-02-11 | Parham Richelle P | director | A - A-Award | Restricted Stock Unit | 742 | 0 |
2022-02-11 | ANDERSON KERRII B | director | A - A-Award | Restricted Stock Unit | 742 | 0 |
2022-02-11 | BELINGARD JEAN-LUC | director | A - A-Award | Restricted Stock Unit | 742 | 0 |
2022-02-11 | Davis Jeffrey A. | director | A - A-Award | Restricted Stock Unit | 742 | 0 |
2022-02-11 | Gilliland Dwight Gary | director | A - A-Award | Restricted Stock Unit | 742 | 0 |
2022-02-11 | Kong Garheng | director | A - A-Award | Restricted Stock Unit | 742 | 0 |
2022-02-11 | NEUPERT PETER M | director | A - A-Award | Restricted Stock Unit | 742 | 0 |
2022-02-04 | BERBERIAN LANCE | EVP, CIO & CTO | A - M-Exempt | Common Stock | 373 | 0 |
2022-02-04 | BERBERIAN LANCE | EVP, CIO & CTO | D - F-InKind | Common Stock | 109 | 277.48 |
2022-02-04 | BERBERIAN LANCE | EVP, CIO & CTO | D - M-Exempt | Restricted Stock Unit | 373 | 0 |
2022-02-04 | Caveney Brian J | EVP, President of Diagnostics | A - M-Exempt | Common Stock | 560 | 0 |
2022-02-04 | Caveney Brian J | EVP, President of Diagnostics | D - F-InKind | Common Stock | 165 | 277.48 |
2022-02-04 | Caveney Brian J | EVP, President of Diagnostics | D - M-Exempt | Restricted Stock Unit | 560 | 0 |
2022-02-04 | EISENBERG GLENN A | Chief Financial Officer, EVP | A - M-Exempt | Common Stock | 970 | 0 |
2022-02-04 | EISENBERG GLENN A | Chief Financial Officer, EVP | D - F-InKind | Common Stock | 286 | 277.48 |
2022-02-04 | EISENBERG GLENN A | Chief Financial Officer, EVP | D - M-Exempt | Restricted Stock Unit | 970 | 0 |
2022-02-04 | Kirchgraber Paul R | CEO, Covance Drug Development | A - M-Exempt | Common Stock | 560 | 0 |
2022-02-04 | Kirchgraber Paul R | CEO, Covance Drug Development | D - F-InKind | Common Stock | 165 | 277.48 |
2022-02-04 | Kirchgraber Paul R | CEO, Covance Drug Development | D - M-Exempt | Restricted Stock Unit | 560 | 0 |
2022-02-04 | Schechter Adam H | President & CEO | A - M-Exempt | Common Stock | 3507 | 0 |
2022-02-04 | Schechter Adam H | President & CEO | D - F-InKind | Common Stock | 1412 | 277.48 |
2022-02-04 | Schechter Adam H | President & CEO | D - M-Exempt | Restricted Stock Unit | 3507 | 0 |
2022-02-04 | Schroeder Mark S | EVP, President-Diagnostics Lab | A - M-Exempt | Common Stock | 560 | 0 |
2022-02-04 | Schroeder Mark S | EVP, President-Diagnostics Lab | D - F-InKind | Common Stock | 152 | 277.48 |
2022-02-07 | Schroeder Mark S | EVP, President-Diagnostics Lab | D - S-Sale | Common Stock | 204 | 277.38 |
2022-02-04 | Schroeder Mark S | EVP, President-Diagnostics Lab | D - M-Exempt | Restricted Stock Unit | 560 | 0 |
2022-02-04 | Seltz Judith C | EVP, CHRO | A - M-Exempt | Common Stock | 280 | 0 |
2022-02-04 | Seltz Judith C | EVP, CHRO | D - F-InKind | Common Stock | 85 | 277.48 |
2022-02-04 | Seltz Judith C | EVP, CHRO | D - M-Exempt | Restricted Stock Unit | 280 | 0 |
2022-02-04 | Summy Amy B. | EVP, Chief Marketing Officer | D - M-Exempt | Restricted Stock Unit | 267 | 0 |
2022-02-04 | Summy Amy B. | EVP, Chief Marketing Officer | A - M-Exempt | Common Stock | 267 | 0 |
2022-02-04 | Summy Amy B. | EVP, Chief Marketing Officer | D - F-InKind | Common Stock | 83 | 277.48 |
2022-02-04 | van der Vaart Sandra D | EVP, Chief Legal Officer | A - M-Exempt | Common Stock | 300 | 0 |
2022-02-04 | van der Vaart Sandra D | EVP, Chief Legal Officer | D - F-InKind | Common Stock | 82 | 277.48 |
2022-02-07 | van der Vaart Sandra D | EVP, Chief Legal Officer | D - S-Sale | Common Stock | 218 | 277.38 |
2022-02-04 | van der Vaart Sandra D | EVP, Chief Legal Officer | D - M-Exempt | Restricted Stock Unit | 300 | 0 |
2022-02-04 | Wilkinson Peter J | SVP, Chief Accounting Officer | D - M-Exempt | Restricted Stock Unit | 150 | 0 |
2022-02-04 | Wilkinson Peter J | SVP, Chief Accounting Officer | A - M-Exempt | Common Stock | 150 | 0 |
2022-02-04 | Wilkinson Peter J | SVP, Chief Accounting Officer | D - F-InKind | Common Stock | 53 | 277.48 |
2022-02-02 | NEUPERT PETER M | director | A - M-Exempt | Common Stock | 771 | 0 |
2022-02-02 | NEUPERT PETER M | director | D - M-Exempt | Restricted Stock Unit | 771 | 0 |
2021-12-14 | ANDERSON KERRII B | director | D - G-Gift | Common Stock | 345 | 0 |
2021-12-14 | ANDERSON KERRII B | director | D - G-Gift | Common Stock | 345 | 0 |
2022-02-02 | ANDERSON KERRII B | director | A - M-Exempt | Common Stock | 771 | 0 |
2021-12-14 | ANDERSON KERRII B | director | D - G-Gift | Common Stock | 860 | 0 |
2022-02-02 | ANDERSON KERRII B | director | D - M-Exempt | Restricted Stock Unit | 771 | 0 |
2022-02-02 | Schroeder Mark S | EVP, President-Diagnostics Lab | A - M-Exempt | Common Stock | 443 | 0 |
2022-02-02 | Schroeder Mark S | EVP, President-Diagnostics Lab | D - F-InKind | Common Stock | 121 | 273.18 |
2022-02-03 | Schroeder Mark S | EVP, President-Diagnostics Lab | D - S-Sale | Common Stock | 161 | 271.81 |